Neuroprotective Effect of Dexomitomidine

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

patient wih mild to moderate traumatic brain injury in ICU will be randomisly distributed into two groups Group I (control group): Patients of this group receive placebo infusion for 72 hours. Group II (DEX group): Patients of this group receive 0.5 ug/kg/hr dexmedetomidine continuous infusion for 72 hour Patient demographics, including age, sex, weight, primary diagnosis, Acute Physiology and Chronic Health Evaluation (APACHE) II score and postresuscitation Glasgow Coma Scale (GCS) score will be collected. CBF will be measured at pre-sedation and after cessation of sedation (dexmedetomidine administration). The CMRe and CMRe/CBF will also be calculated. Measurements of blood gas analysis and haemodynamic parameters [systolic blood pressure (SBP), diastolic blood pressure (DBP), MAP and heart rate (HR)] will be collected at pre-sedation and after cessation of sedation (dexmedetomidine administration).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Dexmedetomidine

Criteria

1. Patients of either sex

2. Age ranged from 18-60 years

3. Patients with mild to moderate traumatic brain injury assessed by CT and 8< GCS < 15 -

Exclusion Criteria:

1 - Patient relative refusal. 2-Severe traumatic brain injury GCS < 8 3-prescence of other organ injury. 4-MAP lower than 80 mmHg 5- hepatic or kidney function dysfunction 6-received any vasoactive agents or sedatives or recieve drugs that affect CBF during the experiment 7- Pregnant.